Asymmetric sensorineural hearing loss is a risk factor for late-onset hearing loss in pediatric cancer survivors following cisplatin treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Asymmetric sensorineural hearing loss is a risk factor for late-onset hearing loss in pediatric cancer survivors following cisplatin treatment

Published:2018-10-18 Issue:1 Volume:66 Page:e27494
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Robertson Margaret S.¹,Hayashi Susan S.²,Camet Miranda L.³^ORCID,Trinkaus Kathryn⁴,Henry Jennifer⁵,Hayashi Robert J.⁵⁶

Affiliation:

1. Davis Audiology; Greenville South Carolina

2. Audiology Division; St. Louis Children's Hospital; St. Louis Missouri

3. Program in Audiology and Communication Sciences; Washington University School of Medicine; St. Louis Missouri

4. Biostatistics Shared Resource; Siteman Cancer Center; Washington University School of Medicine; St. Louis Missouri

5. Division of Pediatric Hematology/Oncology; Department of Pediatrics Washington University School of Medicine; St. Louis Missouri

6. St. Louis Children's Hospital; Washington University School of Medicine; St. Louis Missouri

Funder

Center for Strategic Scientific Initiatives, National Cancer Institute

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.27494/fullpdf

Reference34 articles.

1. Ototoxicity from cisplatin therapy in childhood cancer;Coradini;J Pediatr Hematol Oncol,2007

2. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens;Dean;J Pediatr Hematol Oncol,2008

3. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development;Knight;J Clin Oncol,2005

4. Platinum compound-related ototoxicity in children;Bertolini;J Pediatr Hematol Oncol,2004

5. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy;Weissenstein;Int J Pediatr Otorhinolaryngol,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of hearing screening failures in low‐risk childhood cancer survivors;Pediatric Blood & Cancer;2021-12-02

2. Cisplatin Ototoxicity: Examination of the Impact of Dosing, Infusion Times, and Schedules In Pediatric Cancer Patients;Frontiers in Oncology;2021-06-28

3. Metformin alleviates cisplatin-induced ototoxicity by autophagy induction possibly via the AMPK/FOXO3a pathway;Journal of Neurophysiology;2021-04-01

4. Identifying the mechanisms underlying the protective effect of tetramethylpyrazine against cisplatin‑induced in vitro ototoxicity in HEI‑OC1 auditory cells using gene expression profiling;Molecular Medicine Reports;2020-10-23

5. Patient and Parent Decision-Making in the Setting of Chemotherapy-Induced Sensorineural Hearing Loss;Ear & Hearing;2020-05-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3